| Have been following this for some time...story getting more and more interesting...stock trades around .70 on otc bb...high risk...friday's story at bottom:
(COMTEX) B: VITRO DIAGNOSTICS INC - Files Landmark Patent for Fertili
B: VITRO DIAGNOSTICS INC - Files Landmark Patent for Fertility Drug
New York, New York, Mar 26, 2001 (Market News Publishing via COMTEX) -- Vitro
Diagnostics, Inc. announced that it has filed a patent application with the
United States Patent and Trademark Office entitled "Variant Forms of Human FSH."
Vitro's patent filing provides for unique FSH drug therapy specifically directed
toward the reduction of multiple births, a major adverse effect of present
therapies. The well-publicized birth of septuplets to the McCoughey family in
1997 is an example of the type of unplanned event that Vitro's technology is
designed to help control.
For the first time in the past 30 years, Vitro's technology may result in new
and innovative FSH drugs to lead the treatment of infertility into the 21st
century. In addition to reduction of multiple births, Vitro's new FSH products
may reduce ovarian hyper-stimulation, a rare but serious side effect of current
fertility drugs. Vitro's new invention may also reduce the requirement for daily
injections of fertility drugs, which is presently needed for one to two weeks to
be effective.
The Company's product pipeline includes various forms of purified FSH and
related products for use in the treatment of infertility. A plan for the
approval of its first product, VITROPIN(TM), is under review by the FDA.
VITROPIN(TM) is a highly purified form of urinary FSH produced through the
Company's patented method. Additional patent-pending products include
VITROPIN-C(TM), custom FSH that reduces side effects of current products,
VITROPIN-V(TM), a breakthrough FSH product produced from a proprietary
immortalized cell line, and VITROJECT(TM), a novel drug injection device for
administration of FSH and other drugs.
The new patent filing is related to VITROPIN-C technology and includes methods
of production, composition and uses of these novel forms of human FSH. The
Company presently has one patent issued in the United States (#5,990,288)
concerning processes to purify human and animal FSH. In addition, the Company
has another five pending patent applications, which if issued, would provide
broad patent protection for the Company's pipeline of products to treat human
infertility.
Additional information may be accessed through the Company's web site at
vitrodiag.com.
Certain statements contained herein, which are not historical, constitute
"forward looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. Such forward looking statements are identified by
words such as "intends," "anticipates," "believes," "expects" and "hopes" and
include, without limitation, statements regarding the Company's plan of business
operations, development of products or technologies, receipt of revenues, future
financings and completion of certain transactions. Factors that could cause
actual results to differ materially include, among others set forth in the Form
10-KSB under the caption "Risk Factors," the following: availability of
necessary capital to develop its products, acceptability of the Company's
product in the market place, general economic conditions, competition and
decisions of third parties over which the Company has no control. Most of these
factors are outside the control of the Company. Investors are cautioned not to
put undue reliance on forward-looking statements. Except as otherwise required
by applicable securities statutes or regulations, the Company disclaims any
intent or obligation to update publicly these forward looking statements,
whether as a result of new information, future events or otherwise.
MarketbyFax(tm) - To get the NEWS as it happens, call (604) 689-3041.
(C) 2001 Market News Publishing Inc.
-0-
KEYWORD: New York, New York
*** end of story ***
Vitro Scientists To Present Details of Discovery of New Method To Grow Human Cells for Drug Production and Other Uses
LITTLETON, Colo., May 4 /PRNewswire/ -- Vitro Diagnostics, Inc. (OTC Bulletin Board: VODG - news) announced today that it will present its research concerning new methods for growing human cells in culture at the Annual Meeting of the Endocrine Society to be held in Denver, Colorado on June 20-23, 2001.
In announcing the decision to present this research, Dr. Jim Musick, President and CEO of Vitro, stated, ``The level of interest in this research has been such that we felt the benefits to the scientific research community merited presentation of our results at this point. It is our expectation that discussions of this work will increase exposure possibly leading to establishment of additional partnerships with Vitro. The general interest in the scientific community at large is demonstrated by the fact that NIH has awarded a research grant to Vitro for the study of cellular immortalization.''
Vitro's scientists were able to develop serum-free medium that promotes division of cultured pituitary cells, which is necessary for cellular immortalization. This research also demonstrated that cultured FSH-producing cells responded to physiological stimulation in an appropriate manner, showing that the cultures maintain characteristics of adult cells.
The Company's product pipeline includes various forms of purified FSH and related products for use in the treatment of infertility. Fertility drugs in development include VITROPIN(TM), a highly purified form of human urinary FSH produced by the Company's patented method, VITROPIN-C(TM), custom FSH that reduces side effects of current products, VITROPIN-V(TM), a breakthrough FSH product produced from an immortalized cell line, and VITROJECT(TM), a novel drug injection device for administration of FSH and other drugs.
The Company is also developing a platform technology to immortalize human cells. VITROCELL-X(TM) is the designation of a series of immortalized cell lines in which ``X'' represents the organ from which the cell line was derived, and each of which produces ``natural therapeutic'' products. For example, ``VITROCELL-PG(TM)'' is a cell line derived from the human pituitary gland that produces FSH. VITROCELL-X(TM) cell lines are produced by the Company's patent-pending method, VITROCELL-X(TM) CELL IMMORTALIZATION TECHNOLOGY, which uses controlled over-expression of specific genes to produce cellular immortalization. VITROCELL-X(TM) cell lines may also be used in cell therapeutic approaches to treat diseases resulting from cellular degeneration such as Type I diabetes and Alzheimer's disease.
Certain statements contained herein, which are not historical, constitute ``forward looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as ``intends,'' ``anticipates,'' ``believes,'' ``expects'' and ``hopes'' and include, without limitation, statements regarding the Company's plan of business operations, future financings and completion of certain transactions. Factors that could cause actual results to differ materially include, among others, the following: availability of necessary capital to develop its products, acceptability of the Company's product in the market place, approval of regulatory authorities, general economic conditions, competition and decisions of third parties over which the Company has no control. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise.
MAKE YOUR OPINION COUNT - Click Here
tbutton.prnewswire.com
SOURCE: Vitro Diagnostics, Inc.
Email this story - Most-emailed articles - Most-viewed articles
--------------------------------------------------------------------------------
More Quotes and News: Vitro Diagnostics Inc (OTC BB:VODG.OB - news)
Related News Categories: medical/pharmaceutical
-------------------------------------------------------------------------------- |
|
